Cipher Pharmaceuticals Inc.

TSX:CPH Stock Report

Market Cap: CA$348.3m

Cipher Pharmaceuticals Valuation

Is CPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CPH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CPH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CPH?

Key metric: As CPH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CPH. This is calculated by dividing CPH's market cap by their current earnings.
What is CPH's PE Ratio?
PE Ratio15x
EarningsUS$15.86m
Market CapUS$243.45m

Price to Earnings Ratio vs Peers

How does CPH's PE Ratio compare to its peers?

The above table shows the PE ratio for CPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.2x
GRIN Grown Rogue International
33xn/aCA$197.8m
RX BioSyent
18.1xn/aCA$128.9m
MDP Medexus Pharmaceuticals
19.3x59.7%CA$122.3m
GTII Green Thumb Industries
26.3x27.8%CA$2.4b
CPH Cipher Pharmaceuticals
15x9.4%CA$348.3m

Price-To-Earnings vs Peers: CPH is good value based on its Price-To-Earnings Ratio (15x) compared to the peer average (24.2x).

Price to Earnings Ratio vs Industry

How does CPH's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ATL Atlas Global Brands
0.9xn/aUS$17.41m
MRV Nuvo Pharmaceuticals
1xn/aUS$11.21m
CPTR Captor Capital
0.2xn/aUS$2.16m
SILO Silo Wellness
2.2xn/aUS$1.13m
CPH 15.0xIndustry Avg. 19.4xNo. of Companies6PE01224364860+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CPH is good value based on its Price-To-Earnings Ratio (15x) compared to the North American Pharmaceuticals industry average (19x).

Price to Earnings Ratio vs Fair Ratio

What is CPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CPH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15x
Fair PE Ratio22.3x

Price-To-Earnings vs Fair Ratio: CPH is good value based on its Price-To-Earnings Ratio (15x) compared to the estimated Fair Price-To-Earnings Ratio (22.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CPH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$13.32
CA$16.70
+25.4%
10.1%CA$18.60CA$14.50n/a3
Jan ’26CA$14.32
CA$16.70
+16.6%
10.1%CA$18.60CA$14.50n/a3
Dec ’25CA$15.35
CA$16.70
+8.8%
10.1%CA$18.60CA$14.50n/a3
Nov ’25CA$15.24
CA$16.83
+10.5%
10.9%CA$19.00CA$14.50n/a3
Oct ’25CA$14.69
CA$16.17
+10.1%
7.3%CA$17.00CA$14.50n/a3
Sep ’25CA$18.99
CA$15.83
-16.6%
6.5%CA$17.00CA$14.50n/a3
Aug ’25CA$12.34
CA$13.67
+10.8%
22.8%CA$17.00CA$9.50n/a3
Jul ’25CA$8.20
CA$10.67
+30.1%
8.0%CA$11.50CA$9.50n/a3
Jun ’25CA$8.76
CA$10.67
+21.8%
8.0%CA$11.50CA$9.50n/a3
May ’25CA$8.58
CA$7.62
-11.2%
19.9%CA$9.25CA$5.60n/a3
Apr ’25CA$8.11
CA$7.62
-6.1%
19.9%CA$9.25CA$5.60n/a3
Mar ’25CA$7.22
CA$6.62
-8.4%
15.3%CA$8.00CA$5.60n/a3
Feb ’25CA$5.90
CA$5.53
-6.2%
11.1%CA$6.25CA$4.75CA$13.593
Jan ’25CA$5.54
CA$5.45
-1.6%
9.6%CA$6.00CA$4.75CA$14.323
Dec ’24CA$6.33
CA$5.45
-13.9%
9.6%CA$6.00CA$4.75CA$15.353
Nov ’24CA$4.39
CA$4.33
-1.3%
7.2%CA$4.75CA$4.00CA$15.243
Oct ’24CA$4.25
CA$4.33
+2.0%
7.2%CA$4.75CA$4.00CA$14.693
Sep ’24CA$3.97
CA$4.33
+9.2%
7.2%CA$4.75CA$4.00CA$18.993
Aug ’24CA$3.66
CA$4.33
+18.4%
7.2%CA$4.75CA$4.00CA$12.343
Jul ’24CA$3.57
CA$4.33
+21.4%
7.2%CA$4.75CA$4.00CA$8.203
Jun ’24CA$3.91
CA$4.33
+10.8%
7.2%CA$4.75CA$4.00CA$8.763
May ’24CA$3.43
CA$4.13
+20.3%
3.0%CA$4.25CA$4.00CA$8.582
Apr ’24CA$3.30
CA$4.13
+25.0%
3.0%CA$4.25CA$4.00CA$8.112
Mar ’24CA$3.78
CA$4.13
+9.1%
3.0%CA$4.25CA$4.00CA$7.222
Feb ’24CA$3.42
CA$4.13
+20.8%
3.0%CA$4.25CA$4.00CA$5.902
Analyst Price Target
Consensus Narrative from 3 Analysts
CA$16.70
Fair Value
20.2% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 14:59
End of Day Share Price 2025/02/06 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cipher Pharmaceuticals Inc. is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeByron Capital Markets
Prakash GowdCIBC Capital Markets
David NovakCormark Securities Inc.